Related Experiment Video
Updated: Mar 4, 2026
Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae
Published on: March 7, 2025
ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish
Carles Cornet1, Simone Calzolari2, Rafael Miñana-Prieto3
1ZeClinics SL, PRBB (Barcelona Biomedical Research Park), 08003 Barcelona, Spain. carles.cornet@zeclinics.com.
Abstract:
Toxicity is one of the major attrition causes during the drug development process. In that line, cardio-, neuro-, and hepatotoxicities are among the main reasons behind the retirement of drugs in clinical phases and post market withdrawal. Zebrafish exploitation in high-throughput drug screening is becoming an important tool to assess the toxicity and efficacy of novel drugs. This animal model has, from early developmental stages, fully functional organs from a physiological point of view. Thus, drug-induced organ-toxicity can be detected in larval stages, allowing a high predictive power on possible human drug-induced liabilities. Hence, zebrafish can bridge the gap between preclinical in vitro safety assays and rodent models in a fast and cost-effective manner. ZeGlobalTox is an innovative assay that sequentially integrates in vivo cardio-, neuro-, and hepatotoxicity assessment in the same animal, thus impacting strongly in the 3Rs principles. It Reduces, by up to a third, the number of animals required to assess toxicity in those organs. It Refines the drug toxicity evaluation through novel physiological parameters. Finally, it might allow the Replacement of classical species, such as rodents and larger mammals, thanks to its high predictivity (Specificity: 89%, Sensitivity: 68% and Accuracy: 78%).
Insights
Zebrafish offer a fast, cost-effective method for drug toxicity screening. The ZeGlobalTox assay assesses cardiotoxicity, neurotoxicity, and hepatotoxicity in larval zebrafish, aiding drug development.
Area of Science:
- Drug development
- Toxicology
- Zebrafish models
Background:
- Drug toxicity, including cardiotoxicity, neurotoxicity, and hepatotoxicity, is a major cause of drug attrition.
- Zebrafish are increasingly used in high-throughput screening for drug efficacy and toxicity assessment.
- Larval zebrafish possess fully functional organs, enabling early detection of drug-induced organ toxicities.
Purpose of the Study:
- To introduce ZeGlobalTox, an innovative assay for sequential in vivo assessment of cardiotoxicity, neurotoxicity, and hepatotoxicity in zebrafish.
- To evaluate the potential of zebrafish as a predictive model for human drug-induced toxicities.
- To demonstrate the assay's impact on the 3Rs principles (Reduction, Refinement, Replacement) in animal testing.
Main Methods:
- Sequential in vivo assessment of cardiotoxicity, neurotoxicity, and hepatotoxicity in the same larval zebrafish.
- Utilizing novel physiological parameters for refined toxicity evaluation.
- Validating the assay's predictive power for human drug liabilities.
Main Results:
- The ZeGlobalTox assay integrates multiple toxicity assessments in a single animal.
- The assay demonstrates high predictivity for human drug-induced toxicities (Specificity: 89%, Sensitivity: 68%, Accuracy: 78%).
- The method reduces animal usage by up to 33% compared to traditional methods.
Conclusions:
- Zebrafish serve as a valuable, cost-effective model bridging in vitro assays and rodent studies for drug safety evaluation.
- ZeGlobalTox enhances drug toxicity assessment, aligning with the 3Rs principles.
- The high predictivity of the assay suggests potential for replacing classical animal models in drug development.
